You are here: Industry Insights > Novartis

News List

Long-term survival benefit shown for metastatic melanoma patients treated with Novartis Tafinlar® + Mekinist® worldpharmanews
June 10, 2019
Long-term survival benefit shown for metastatic melanoma patients treated with Novartis Tafinlar® + Mekinist®.
Novartis hits targets in late-stage QMF149 asthma trial pharmatimes
June 05, 2019
Novartis has announced that a phase III QUARTZ study of its investigational inhaled combination treatment, QMF149, has met primary and key secondary endpoints in patients with inadequately controlled asthma.
Novartis hits targets in late-stage QMF149 asthma trial pharmatimes
June 03, 2019
The combo is currently in development for the treatment of inadequately controlled asthma in patients who remain symptomatic despite current treatment.
Novartis’ Kisqali hits endpoints in Phase III breast cancer trial pharmatimes
June 03, 2019
The overall survival results were presented as a late-breaker at the 2019 ASCO Annual Meeting and will be published in The New England Journal of Medicine.
Novartis’ Piqray Approved as First PI3K Inhibitor for Breast Cancer drugs
June 03, 2019
Novartis’ Piqray Approved as First PI3K Inhibitor for Breast Cancer.
Zolgensma: First Gene Therapy for Pediatric Spinal Muscular Atrophy (SMA) drugs
June 03, 2019
First Gene Therapy for Pediatric Spinal Muscular Atrophy (SMA).
FDA approves Novartis’ Piqray as the first drug targeting PIK3CA mutation pharmaceutical-technology
May 30, 2019
Novartis has announced the US Food and Drug Administration (FDA) has approved its drug Piqray (alpelisib) as the first PIK3CA inhibitor.
Novartis’ gene therapy Zolgensma gets FDA sign-off pharmaceutical-technology
May 29, 2019
Novartis subsidiary AveXis has received approval from the US Food and Drug Administration (FDA) for Zolgensma to treat children with spinal muscular atrophy (SMA).
Novartis grabs blockbuster cancer nod for Piqray on double good news day fiercepharma
May 29, 2019
Novartis’ promise of 25 potential blockbuster launches is steadily coming to fruition. On the same day the FDA approved gene therapy Zolgensma, the U.S. regulator also waved through breast cancer drug Piqray.
Novartis CEO touts 25 potential—and diverse—blockbuster launches. But is its portfolio too scattered? fiercepharma
May 29, 2019
Just over a year into his reign as Novartis CEO, Vas Narasimhan proudly spotlighted 25 potential blockbuster launches coming down the pipeline. But that figure also begs the question: Is the company dabbling in too many different therapeutic areas and pla

Previous page 1 2 3 4 5 6 7 8 9 10 ... 71 72 Next page